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Background: Recurrent respiratory infections are one of the most important causes of morbidity in childhood.
When immune functions are still largely immature, the airway epithelium plays a primary defensive role since,
besides providing a physical barrier, it is also involved in the innate and the adaptive immune responses. A study
was therefore designed to evaluate in vitro whether pidotimod, a synthetic dipeptide able to stimulate the
inflammatory and immune effector cells, could activate bronchial epithelial cell functions involved in response to
infections.
Methods: BEAS-2B cell line (human bronchial epithelial cells infected with a replication-defective Adenovirus
12-SV40 virus hybrid) were cultured in the presence of pidotimod, with or without tumor necrosis factor (TNF)-α or
zymosan to assess: a) intercellular adhesion molecule (ICAM)-1 expression, by flow cytometry; b) toll-like receptor
(TLR)-2 expression and production, by immunofluorescence flow cytometry and western blotting; d) interleukin
(IL)-8 release, by enzyme-linked immunosorbent assay (ELISA); e) activated extracellular-signal-regulated kinase
(ERK1/2) phosphorylation and nuclear factor-kappa B (NF-kB) activation, by western blotting.
Results: The constitutive expression of ICAM-1 and IL-8 release were significant up-regulated by TNF-α (ICAM-1)
and by TNF-α and zymosan (IL-8), but not by pidotimod. In contrast, an increased TLR-2 expression was found after
exposure to pidotimod 10 and 100 μg/ml (p < 0.05) and to the association pidotimod 100 μg/ml + TNF-α (p < 0.05).
Western blot analysis substantiated that the constitutive TLR-2 expression was significantly increased after exposure
to all the stimuli. Finally, while a remarkable inhibition of TNF-α -induced ERK1/2 phosphorylation was observed in
the presence of pidotimod, both TNF-α and pidotimod were effective in inducing NF-kB protein expression in the
cytoplasm and its nuclear translocation.
Conclusion: Through different effects on ERK1/2 and NF-kB, pidotimod was able to increase the expression of
TLR-2 proteins, surface molecules involved in the initiation of the innate response to infectious stimuli. The lack of
effect on ICAM-1 expression, the receptor for rhinovirus, and on IL-8 release, the potent chemotactic factor for
neutrophils (that are already present in sites of infection), may represent protective functions. If confirmed in vivo,
these activities may, at least in part, clarify the mechanism of action of this molecule at airway level.
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Respiratory tract infections, presenting as common cold,
rhinosinusitis, tonsillopharyngitis, otitis media and tracheo-
bronchitis, with or without airway obstruction, are highly
prevalent among young children [1-3]. These infections
have not only an impact on children’s health and
well-being, but also generate high medical costs and indi-
rect costs for the family and the society [4,5]. Indeed, on
average, young children experience 4–6 upper respiratory
tract infections per year [6], but when they grow older, the
incidence of these infections decreases, probably as a result
of a more mature immune defenses and improved
anatomical conditions. The most common pathogens
involved in the etiology of recurrent respiratory infections
are human rhinoviruses (HRV), adenovirus, parainfluenza
virus, respiratory syncytial virus, enterovirus, human
metapneumovirus and coronavirus, in addition to influ-
enza viruses and rhinovirus [6,7]. A major pathogenetic
role is played by rhinoviruses, the most frequent causa-
tive agents of both upper and lower respiratory tract in-
fections in infants and young children that are able to
induce a broad variety of clinical outcomes, ranging
from asymptomatic infections to severe respiratory dis-
eases requiring hospitalization [6,8].
Being protected by a highly specialized innate and
adaptative immune system, the surface of the respiratory
tract acts as a selective barrier, maintaining the integrity
of tissue compartments and impeding entry of inhaled
majority microbial pathogens, irritants and allergens [9].
Besides providing a physical and functional barrier to
external agents, airway epithelial cells are also actively in-
volved in initiation of the host inflammatory and immune
responses through the release of early inflammatory me-
diators [9,10]. Through the activation of their surface
pattern recognition receptors, that detect environmental
stimuli, airway epithelial cells secrete endogenous danger
signals, thereby activating dendritic cells and bridging
innate and adaptive immunity [9-11].
Extensive research into the role of inflammatory me-
diators in the pathogenesis of respiratory insufficiency
syndrome (RIS), has produced evidence for increased
concentrations of several mediators, such as kinins,
leukotrienes, histamine, interleukins 1, 6, and 8, tumor
necrosis factor (TNF)-α, and regulated by activation
normal T cell expressed and secreted (RANTES) in the
nasal secretions of patients with colds [12-14]. The host
response mechanisms triggered by viral infection and their
efficacy in protecting the host are, however, extremely
complex and far from being resolved. Furthermore an ex-
aggerated inflammatory reaction, may increase the damage
at airway levels, rather than protect from infection [12-15].
Several studies have shown that atopy and attendance at
large daycare are associated with more common respira-
tory infections during the preschool years [16,17], whileonly in a minority of patients partial IgA and/or IgG
subclass deficiency can be demonstrated [18]. However, a
defective (immature) inflammatory and/or immune re-
sponse at airway epithelial level may also be involved [19].
With this background a study was designed to evaluate
in vitro whether pidotimod, a synthetic dipeptide active on
both innate and adaptive immunity [20], could modulate
airway epithelial cells functions involved in the response to
respiratory infections. We evaluate intercellular adhesion
molecule (ICAM)-1 and toll like receptor (TLR)-2 expre-
ssion, interleukin (IL)-8 release and investigate the possible
involvement of the protein complex nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) and the




A human bronchial epithelial cells line (BEAS-2B)
(ATCC, Manassas, VA, USA), derived from human bron-
chial epithelium transformed by an adenovirus (12-SV40
hybrid virus) was used in all the experiments [21]. These
cells, that retain electron microscopic features of epithe-
lial cells and show positive staining with antibodies to
cytokeratin, were grown as monolayer in a 1:1 mixture
of Laboratory of Human Carcinogenesis (or LHC)-9
medium (Invitrogen SRL; Milan, Italy) and RPMI 1640
medium (EuroClone; Milan, Italy).
Pidotimod preparation
Pidotimod (99.6% purity) was gently provided by Valeas
S.p.A. (Milan, Italy). Stock standard solution was pre-
pared in PBS at the concentration of 35 mg/ml [20].
Assessment of cell viability
BEAS-2B were treated with pidotimod (10, 100 μg/ml),
10 ng/ml TNF-α or 50 μg/ml zymosan used alone or in
association, at different time (24 and 48 h), the percent
viability was measured by trypan blue dye exclusion test
(EuroClone S.p.A., Mi, Italy) [22]. Cells were counted in
a Neubauer chamber and viable cells were detected
based on the ability to exclude the dye. Non-viable cells
were blue due to defects in the cell membrane.
Flow cytometry
BEAS-2B cells were grown to 90% confluence in 12 well
culture plate in the presence of pidotimod (10 and 100
μg/ml), 10 ng/ml TNF-α, 50 μg/ml zymosan used alone
or in association, or pre-treated with pidotimod for dif-
ferent time and then stimulated with TNF-α or zymosan
for another 24 h. For each analysis 2 × 106 cells were in-
cubated with FITC-Conjugated mouse anti ICAM-1
(Invitrogen S.r.l., San Giuliano Milanese, Italy) and with
an anti-mouse TLR-2 (Santa Cruz Biotechnology Inc,
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pression was detected using a goat anti-mouse antibody
(Alexa Fluor488; Invitrogen). The cells were washed,
resuspended in PBS and immediately analyzed with
FACS Calibur flow cytometer (Becton Dickson, Milan,
Italy) using Cell Quest software [22]. Mean fluorescent
intensity was compared with control staining using an
irrelevant isotype-matched mouse monoclonal antibody.
Immunofluorescence microscopy
BEAS-2B cells were cultured on 8-well glass Labtek
slides (Nalge Nunc International) under different experi-
mental conditions. The cells were treated with 100 μg/ml
pidotimod or 10 ng/ml TNF-α used alone or in asso-
ciation, for 24 h. BEAS-2B cells were fixed in ice-cold
methanol for 5 min. After blocking BEAS-2B were la-
belled with mouse anti TLR-2 Abs (TL2.1; Santa Cruz
Biotechnology), then with a goat anti-mouse antibody
(Alexa Fluor488; Invitrogen).
IL-8 assay
BEAS-2B cells were incubated for 24 h with 10 ng/ml
TNF-α, 50 μg/ml zymosan or pidotimod (10, 100 μg/ml),
in the absence or presence of TNF-α and zymosan. After
the treatments the supernatant were collected and IL-8
levels were quantified by enzyme-linked immunosorbent
assay (ELISA) kits (R&D Systems, Minneapolis, USA),
according to the manufacturer’s instructions.
Preparation of cytoplasmic extracts for TLR-2 analysis and
activated extracellular-signal-regulated kinase (ERK)1/2
analysis
For TLR-2 analysis, BEAS-2B cells were grown to 90%
confluence in 24 well plates and treated with pidotimod
(10, 100 μg/ml), 10 ng/ml TNF-α, 50 μg/ml zymosan, used
alone or in association, for 24 h. For ERK1/2 analysis, cells
were equally plated and cultured until 90% confluence
and then exposed to pidotimod, TNF-α or TNF-α with
pidotimod, for 5 to 60 min [23]. After the treatments the
cells were scraped and lysed with lysis buffer [20 mM
Tris–HCl buffer (pH 7.4)], containing 150 mM NaCl, 1
mM EDTA, 1nM EGTA, 1 mM sodium orthovanadate,
1% (v/v) Triton X-100, 1 mM PMSF, 10 μg/ml leupeptin,
and 10 μg/ml aprotinin) for 5 min on ice. The lysates were
then centrifuged at 12,000 g for 5 min [23].
Preparation of cytoplasmic and nuclear extracts for NF-kB
analysis
BEAS-2B cells were grow to 90% confluence in 6 well
plates and treated with 100 μg/ml pidotimod, TNF-α or
TNF-α with pidotimod for 1 h. Extracts were prepared
using a method described by Leslie J. Crofford [24].
Briefly, cells resuspended in cytoplasmic buffer (10 mM
HEPES, pH 7.9, 10 mM KC1, 0.1 mM EDTA, 0.1 mMEGTA, 1 mM dithiothreitol [DTT], and protease inhibi-
tors) on ice for 15 minutes, after which Triton X-100 was
added to a final concentration of 0.25%. Intact nuclei were
pelleted by centrifugation, and the cytoplasmic extract
was immediately frozen. Nuclei were resuspended in high-
salt buffer (20 mM HEPES, pH 7.9, 400 mM NaCI, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT, and protease inhibitors)
for 15 min at 4°C. The nuclear extract was collected after
centrifugation at 13,500 g for 5 min at 4°C.
Western blot analysis
The protein concentration of the lysates was measured
using the Bio-Rad protein assay. Equal amounts of protein
were resolved with 10% or 12% SDS-PAGE and trans-
ferred to PVDF membranes. Membranes were blotted for
TLR-2 and p65 NF-kB (Santa Cruz Biotechnology), total
ERK1/2 and phosphorylated ERK1/2 (Cell Signaling,
Technology, Beverly, MA, USA), GAPDH (Novus Bio-
logical, Inc, Segrate, Milan, Italy), Lamin A/C (Santa Cruz
Biotechnology Inc, Segrate, Milan, Italy) [23]. After incu-
bation with HPR-conjugated anti-rabbit o anti-mouse anti-
body (Cell Signaling Technology), the bands were detected
using enhanced chemoluminescence (ECL, Pierce, Celbio,
Italy) and relevant band intensities were quantified using a
Versadoc Imaging System model 3000 (Biorad Laborato-
ries, Hercules, CA, USA).
Statistical analysis
Statistical evaluation was performed using the statistical
software package GraphPad Prism 3.02 (GraphPad Soft-
ware, San Diego, CA, USA). The results were expressed
as mean ± standard error of the mean (SEM) and t test
or the Mann–Whitney test were used. Probability values
(P < 0.05) were considered as statistically significant.
Results
Airway epithelial cell viability
Assessment of BEAS-2B cells by trypan blue dye exclu-
sion test showed that after 24 h incubation, cell viability
> 90% and was similar in cultures containing pidotimod
(10 e 100 μg/ml), zymosan, TNF-α or pidotimod plus
zymosan or TNF-α (not shown). Similar results were
obtained exposing BEAS-2B cells for 48 h (not shown).
ICAM-1 expression by airway epithelial cells
To investigate the effect of pidotimod on ICAM-1 ex-
pression, BEAS-2B cells were exposed to pidotimod (10,
100 μg/ml), TNF-α (10 ng/ml) or pre-treated with
pidotimod for different time (4, 12 or 24 h) and then
stimulated with TNF-α for additional 24 h. The cells
were stained with antibody anti-human ICAM-1. Result
obtained by flow cytometric analysis showed that the
constitutive expression of ICAM-1 by BEAS-2B cells
was significant up-regulated by 24 h exposure of the
Figure 1 ICAM 1 expression in BEAS-2B cells. Flow cytometric
analysis of ICAM-1 expression on cells: A) untreated (CTR), treated
with TNF-α or pidotimod (pid 10 and 100 μg/ml) for 24 h; B) treated
with 100 μg/ml pidotimod for different time periods (24, 36 and
48 h); C) pre-treated with pidotimod for different time (4, 12 and
24 h) and then stimulated with TNF-α for additional 24 h. ICAM-1
expression is quantified as mean fluorescence intensity (MFI) on the
ordinate and the different culture conditions are shown on the
abscissa. The data are expressed as mean ± SEM. *p < 0.05 versus
control. The results shown are representative of three
independent experiments.
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No changes in ICAM-1 expression were obtained expos-
ing the cells to pidotimod for 36 h or 48 h (Figure 1B) and
no modifications in the TNF-α -induced increase in
ICAM-1 expression was observed pre-treating the cells
with pidotimod for 4, 12 or 24 h (Figure 1C).
TLR-2 expression by airway epithelial cells
To analyze the expression of TLR-2, BEAS-2B cells were
exposed for 24 h to pidotimod (10 and 100 μg/ml),
TNF-α, zymosan or pidotimod with TNF-α or zymosan.
The enhanced TLR-2 expression induced by exposure to
the stimuli detected by immunofluorescence microscopy
(Figure 2A) was then quantified by flow cytometric ana-
lysis and found to be significant only after exposed to
pidotimod 10 or 100 μg/ml (p < 0.05) and the association
pidotimod 100 + TNF-α (p < 0.05) (Figure 2B). Western
blot (Figure 3A) and densitometric analysis demon-
strated that, at protein level, the effect was statistically
significant also for TNF-α (p < 0.05), zymosan (p < 0.01)
and for the combinations zymosan with pidotimod (p <
0.01) (Figure 3B). Pre-incubation of the cells with
pidotimod for 4, 12 or 24 h did not modify the results
(not shown).
IL-8 release
BEAS-2B cells were exposed for 24 h to pidotimod (100
μg/ml), TNF-α, zymosan or TNF-α and zymosan with
pidotimod. The detectable IL-8 concentrations found in
the supernatants of cell cultured in medium alone, were
significantly increased in cell culture exposed for 24 h to
TNF-α or zymosan (p < 0.01, each comparison), but not
to pidotimod (Figure 4). No further modifications in the
TNF-α - or zymosan-induced increase in IL-8 release was
observed with the addition of pidotimod to the cell cul-
tures. Finally, preincubation of the cells with pidotimod
did not modify the results (not shown).
ERK1/2 pathway activation
For ERK1/2 analysis, confluent BEAS-2B cells were
exposed to pidotimod, TNF-α or TNF-α with pidotimod
for 5 to 60 min. An increase threonine/tyrosine phos-
phorylation of ERK1/2 was already detectable by
Western blotting at 5 min in cell exposed to TNF-α, but
not to pidotimod (100 μg/ml) (Figure 5A). In contrast,
the addition of pidotimod (100 μg/ml) to the cells exposed
to TNF-α induced a detectable decrease in ERK1/2 phos-
phorylation (Figure 5A). Densitometric analysis demon-
strated that the inhibitory effect was complete at 5, 30 and
60 min (Figure 5B).
NF-kB expression and translocation
BEAS-2B cells were treated with TNF-α, 100 μg/ml
pidotimod or TNF-α with pidotimod for 1h. NF-kB was
Figure 2 Immunofluorescence and flow cytometry analysis of TLR-2 expression induced by pidotimod. (A) Representative images of TLR-
2 expression collected by fluorescence microscopy in cell cultures untreated (CTR) or treated with TNF-α, zymosan, pidotimod (Pid 100 μg/ml) or
pidotimod (Pid 100 μg/ml) plus TNF-α for 24 h; B) Histograms displaying the flow cytometric analysis of TLR-2 expression on cells treated with
TNF-α, zymosan, pidotimod (Pid 10, 100 μg/ml), or pidotimod (Pid 100 μg/ml) plus TNF-α (TNF-α Pid or zymosan (Zym + Pid, for 24h. TLR-2
expression is quantified as mean fluorescence intensity (MFI) on the ordinate and the different culture conditions are shown on the abscissa. The
data are expressed as mean ± SEM.*p < 0.05 versus control. The results shown are representative of three independent experiments.
Figure 3 Western blot analysis of TLR-2 expression induced by
pidotimod. (A) Representative western blot of TLR-2 and GAPDH
expression of BEAS-2B incubated with medium alone (CTR) or
treated with TNF-α, zymosan (Zym), pidotimod (Pid 100 μg/ml) or
pidotimod (Pid 100 μg/ml) plus TNF-α or zymosan (Zym), for 24 h.
(B) The densitometric analysis of TLR-2 expression, normalized to
GAPDH, is shown on the ordinate and the different culture
conditions on the abscissa. The data are expressed as mean ± SEM.
*p < 0.05 and **p < 0.01 versus control. The results shown are
representative of three independent experiments.
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clear extracts. NF-kB p-65 expression was upregulated
in the cytoplasmic compartment after exposure to TNF-
α or pidotimod and associated with NF-kB nuclear
translocation (Figure 6A and B). Similar results were
obtained in the experiments performed with pidotimod
10 μg/ml (not shown).Figure 4 Assessment of IL-8 secretion. IL-8 concentration in the
supernatants of BEAS-2B incubated with medium alone (CTR) or
treated with TNF-α zymosan (Zym), pidotimod (Pid 100 μg/ml),
TNF-α and pidotimod (TNF-α, Pid or zymosan and pidotimod
(Zym + Pid for 24 h, evaluated by ELISA. IL-8 are expressed as mean ±
SEM. **p < 0.01 versus control.
Figure 5 Detection by Western blot of ERK1/2 phosphorylation. (A) Representative western blot of phosphorylated and total ERK1/2 of
BEAS-2B cells untreated (CTR) or exposed to TNF-α or pidotimod (Pid) for 5 min or TNF-α with pidotimod (TNF-α + Pid) for 5 to 60 min. (B) The
densitometric analysis of ERK1/2 phosphorylation, normalized to total ERK1/2 is shown on the ordinate and the different culture conditions on
the abscissa. The data are expressed as mean ± SEM.*p < 0.05 versus control. The results shown are representative of three independent experiments.
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Using the BEAS-2B human bronchial epithelial cells line
we have shown that pidotimod is able to induce in vitro
cellular changes potentially useful in enhancing the
capability of the host to fight respiratory infections. We
found that exposure of BEAS-2B cells to pidotimod had
no effect on ICAM-1 expression and IL-8 release, while
a detectable upregulation of TLR-2 expression wasFigure 6 Detection by Western blot of NF-kB expression. (A) Represen
nuclear extracts of BEAS-2B cultured with medium alone (CTR) or exposed
(TNF-α + Pid 100) for 24 h. GAPDH and Laminin A/C were used as houseke
to GAPDH (cytoplasm) or laminin A/C (nucleus), are shown on the ordinate
expressed as mean ± SEM. *p < 0.05 versus control. The results shown are robserved by fluorescence microscopy, cytofluorimetry
and western blot analysis. Pidotimod was also effective
in inducing a remarkable inhibition of TNF-α-induced
ERK1/2 phosphorylation and, at the opposite, a signifi-
cant increase in NF-kB protein expression and NF-kB
nuclear translocation.
Pidotimod is a synthetic dipeptide molecule with bio-
logical and immunological activity on both the adaptivetative western blots for NF-kB p65 levels in the cytoplasm and in the
to TNF-α, 100 μg/ml pidotimod (Pid 100), or TNF-α and pidotimod
eping protein. (B) The densitometric analysis of NF-kB data, normalized
and the different culture conditions on the abscissa. The data are
epresentative of three independent experiments.
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both from animal and human specimens, have demon-
strated a significant activity on both the innate and the
adaptive immune responses, explaining the remarkable
results of the clinical studies, where reduction in the rate
of recurrent infections of the upper respiratory tract has
been observed [25-27].
Emerging evidence from epidemiologic, clinical and
animal studies indicates that viral infections, the leading
cause of respiratory morbidity in young children, is an
important environmental stimulus for airway injury and
remodeling, resulting in bronchial hyperreactivity, im-
paired lung function and, potentially, persistent asthma
[28]. The availability of PCR techniques has lead to a
significant improvement in virus detection rate and shown
that HRVs, principally known as the “common cold”
viruses, are involved in the pathogenesis of wheezing dis-
orders in 41-45% of young children [29]. Approximately
90% of the different HRV serotypes known utilize, as
specific receptor ICAM-1, a molecule expressed on the
surface of airway epithelial cells [30]. HRV infection
upregulates ICAM-1 expression on airway epithelial cells,
thus facilitating further viral attachment and entry [31].
Besides being a major receptor for HRVs, ICAM-1 is also
involved in the transmigration across airway epithelial
monolayers of neutrophils and their activation [32], and in
disorders characterized by neutrophil-mediated acute lung
injury [33]. Therefore the observation that in our experi-
mental model pidotimod did not increase the constitutive
or the TNF-α -induced ICAM-1 expression may be inter-
preted as a “protective function”, to avoid enhanced
susceptibility to human HRV and neutrophil-mediated
damage to the airway surface. A similar interpretation can
be made for the results on IL-8 release.
IL-8 is a powerful chemotactic and paracrine mediator
for neutrophils, and infiltration of activated neutrophils
play a key role in pulmonary inflammation and oxidative
injury [34], a characteristic feature of respiratory viral
infections [35,36].
On the contrary, pidotimod enhanced the constitutive
TLR-2 expression, raising questions on the activity of
pidotimod on airway epithelial cells. The expression of
surface molecules (such as ICAM-1 and TLR-2) is regu-
lated not only by different stimuli [31,37,38] but also by
dissimilar intracellular pathways that may be triggered by
the same stimulus [38-41]. An example is the activity
of IFN-γ, able to have opposite effects on ICAM-1 and
TLR-2 expression (up- and down-regulation, respectively)
on different cell types [37,38,42]. The characteristics of
pidotimod, to be able to regulate differently the expression
of surface molecules has already been demonstrated by
Gourgiotis D. and co-workers [43]. Using blood mono-
nuclear cells, isolated from atopic asthmatic and normal
children, they showed that through unknown intracellularmechanisms pidotimod downregulated the expression of
CD30 induced by phytohaemoagglutinin but had no effect
on human leukocyte antigen (HLA)-DR molecules [43].
TLRs are a class of proteins that play a key role in the in-
nate immune system, recognizing structurally conserved
molecules derived from microbes [44]. TLRs are a type of
pattern recognition receptor and recognize molecules that
are broadly shared by pathogens but distinguishable from
host molecules, collectively referred to pathogen-associated
molecular patterns (PAMPs). Of the ten mammalian TLR
proteins identified thus far, TLR-2 seems to be the least
discriminating, since it recognizes many bacterial, fungal,
viral, and certain endogenous substances [44,45]. Recogni-
tion of PAMPs results in internalization and phagocytosis
of bound molecules and in cellular activation with release
of cytokines, chemokines and various interleukins [44,45].
Cytokines participating in this “nonspecific” immune
defense include various interleukins, such as TNF-α, IL-1α,
IL-1β, IL-6, IL-8 and IL-12. PAMPs-TLR interactions on
the surface of the cells are sufficient to activate the Ca2+
fluxes associated with induction of NF-kB in the airway
[46]. Recent studies have implicated TLR, and especially
TLR-2 and TLR-4, as sentinel receptors able to signaling
the interaction of the host cells with bacterial pathogens via
an NF-kB-mediated pathway [47]. Interestingly, using
murine macrophages it was shown that TLR-2 mRNA may
be induced after bacterial infection with the involvement of
several cytokines, including IL-1 α, and GM-CSF, but that
NF-kB is necessary for maximal TLR-2 transcription [48],
further underlining the tight connections between NF-kB
and TLR-2.
The different effects of pidotimod on BEAS-2B cells
here reported may be at least partially explained by the
opposite effects on some cell functions produced by
ERK1/2 phosphorylation or NF-kB activation.
Extracellular-signal-regulated kinases (ERKs) or classical
mitogen-activated protein (MAP) kinases are widely
expressed protein kinase intracellular signalling molecules
that are engaged in the regulation of meiosis, mitosis, but
also in several post mitotic functions, including activities
involved in inflammatory and defense processes [49,50].
These include opposite effects on ICAM-1 and TLR-2
expression. In agreement with our results on BEAS-2B
cells, stimulation of ERK1/2 phosphorylation by cysteinyl
leukotriene D4 resulted in an increased ICAM-1 expre-
ssion by 16HBE bronchial epithelial cells, associated with
enhanced eosinophil adhesion [51]. In contrast, inhibition
of ERK1/2 phosphorylation [52] by up-regulation of MAP
kinase phosphatase-1 by glucocorticoids increased TLR-2
expression by HeLa epithelial cells.
NF-kB is a protein complex, found in almost all animal
cell types, that controls DNA transcription and is in-
volved in cellular responses to a variety of stimuli such
including bacterial or viral antigens [53,54]. NF-kB plays
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tions because it belongs to the category of “rapid-acting”
primary transcription factors, i.e. present in cells in an
inactive state and not requiring new protein synthesis to
be activated and is involved in the regulation of reactive
oxygen species, cytokines and adhesion molecules produc-
tion [54-57].
The identification of TLRs as specific pattern recogni-
tion molecules and the finding that, not only their ex-
pression is regulated by NF-kB [42], but also that TLR
stimulation leads to NF-kB activation has improved our
understanding on both the innate and the adaptive im-
mune responses to infections.
Surprisingly, NF-kB activation induced by pidotimod
did not result in an increase in IL-8 release. However, in
human airway epithelial cell cultures and in mice inhi-
bition of ERK1/2 phosphorylation suppress IL-8 produc-
tion induced by exposure to sub toxic doses of cadmium
[58]. Moreover, other transcriptional factors are involved
in IL-8 production and release, including activator
protein 1 (AP-1), and signal transducer and activator
of transcription proteins (STAT) [59,60]. Rather than
pidotimod, elevated intracellular levels of reactive oxy-
gen species (ROS) in lung epithelial cells can activate
these pathways [60,61]. Therefore, upstream of these
transcriptional factors, ROS-sensitive signaling pathways,
including mitogen-activated protein kinases and protein
kinase C, may be involved in the increase in inflamma-
tory gene activation [56,57].
Conclusion
We have shown that pidotimod, a synthetic dipeptide
used in the prevention of recurrent respiratory infection
in children, is able to modulate airway epithelial cells
functions involved in host-virus possibly through NF-kB
activation. The obvious limitation of the study is that the
experiments here reported were obtained in a human
cell line. If confirmed in vivo, these activities may, at
least in part, clarify the mechanism of action of this mol-
ecule at airway level.
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